materials atr Search Results


90
PIKE Technologies the atr accessory is a horizontal flow cell equipped with an amorphous material transmitting ir radiation (amtir) crystal
The Atr Accessory Is A Horizontal Flow Cell Equipped With An Amorphous Material Transmitting Ir Radiation (Amtir) Crystal, supplied by PIKE Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/the atr accessory is a horizontal flow cell equipped with an amorphous material transmitting ir radiation (amtir) crystal/product/PIKE Technologies
Average 90 stars, based on 1 article reviews
the atr accessory is a horizontal flow cell equipped with an amorphous material transmitting ir radiation (amtir) crystal - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Applied Biological Materials Inc atr-i774yfs*5-gfp
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Atr I774yfs*5 Gfp, supplied by Applied Biological Materials Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atr-i774yfs*5-gfp/product/Applied Biological Materials Inc
Average 90 stars, based on 1 article reviews
atr-i774yfs*5-gfp - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
EIPICO Inc materials atr (cas number 134523-03-8)
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Materials Atr (Cas Number 134523 03 8), supplied by EIPICO Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/materials atr (cas number 134523-03-8)/product/EIPICO Inc
Average 90 stars, based on 1 article reviews
materials atr (cas number 134523-03-8) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
EIPICO Inc materials atr
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Materials Atr, supplied by EIPICO Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/materials atr/product/EIPICO Inc
Average 90 stars, based on 1 article reviews
materials atr - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Bruker Corporation atr-ftir bruker model alpha with diamond crystal atr material
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Atr Ftir Bruker Model Alpha With Diamond Crystal Atr Material, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atr-ftir bruker model alpha with diamond crystal atr material/product/Bruker Corporation
Average 90 stars, based on 1 article reviews
atr-ftir bruker model alpha with diamond crystal atr material - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
PIKE Technologies atr reference standard material 162-5470
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Atr Reference Standard Material 162 5470, supplied by PIKE Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atr reference standard material 162-5470/product/PIKE Technologies
Average 90 stars, based on 1 article reviews
atr reference standard material 162-5470 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
PHARAONIA Pharmaceuticals standard materials atorvastatin (atr) (i.s)
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Standard Materials Atorvastatin (Atr) (I.S), supplied by PHARAONIA Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/standard materials atorvastatin (atr) (i.s)/product/PHARAONIA Pharmaceuticals
Average 90 stars, based on 1 article reviews
standard materials atorvastatin (atr) (i.s) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
PIKE Technologies nine-reflection amtir (amorphous material transmitting infrared radiation) horizontal atr (hatr) accessory
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Nine Reflection Amtir (Amorphous Material Transmitting Infrared Radiation) Horizontal Atr (Hatr) Accessory, supplied by PIKE Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nine-reflection amtir (amorphous material transmitting infrared radiation) horizontal atr (hatr) accessory/product/PIKE Technologies
Average 90 stars, based on 1 article reviews
nine-reflection amtir (amorphous material transmitting infrared radiation) horizontal atr (hatr) accessory - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Sadtler Research Laboratories atr/ftir spectra of inorganic materials
(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR <t>I774Yfs*5/Nfs*3</t> mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).
Atr/Ftir Spectra Of Inorganic Materials, supplied by Sadtler Research Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/atr/ftir spectra of inorganic materials/product/Sadtler Research Laboratories
Average 90 stars, based on 1 article reviews
atr/ftir spectra of inorganic materials - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


(A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR I774Yfs*5/Nfs*3 mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).

Journal: bioRxiv

Article Title: ATR-I774Yfs*5 promotes genomic instability through micronuclei formation

doi: 10.1101/2022.03.10.483800

Figure Lengend Snippet: (A) Lollipop plot of ATR mutations across all cancer types; there is a mutational hotspot at the codon 774 which occurs at a far greater frequency compared to any other ATR mutation. (B) Distribution pattern of all identified ATR I774Yfs*5/Nfs*3 mutations from publicly available databases; cancers typically associated with microsatellite instability (colorectal, endometrial, gastric, and pancreatic cancers) account for about two thirds of all identified ATR-I774Yfs*5/Nfs*3 mutations. (C) Nucleotide context of these truncation mutations show they are frameshifts that occurs as the result of a single adenosine insertion (I774Nfs*3) or deletion (I774Yfs*5) in a poly-adenosine region of ATR producing a truncation mutation at codon 776 (TAG stop codon) or codon 778 (TAA stop codon) for the insertion or deletion events, respectively. While the insertion or deletion of a single A could theoretically occur at any nucleotide along the poly-adenosine sequence, the resulting amino acid change only begins at codon 774 (boxed). (D) Co-incidence between all observed ATR-I774Yfs*5/I774Nfs*3 mutations and mutations in genes in the MutSα /MutLα complexes. Some ATR mutants were co-incident with multiple MutSα/MutLα complex genes, while some had no co-incidence. (E) A map of the functional domains of ATR, showing the location of the mutation of interest, ATR-I774Yfs*5 (F) ATR-I774Yfs*5/I774Nfs*3 mutations generate a putative truncated ATR product which lacks numerous functional domains including the C-terminal kinase domain but still retains the RPA and ATRIP interaction domains as well as the nuclear localization sequence (NLS).

Article Snippet: ATR-I774Yfs*5-GFP is a modification of the ATR-WT-GFP PCDNA 3.1 plasmid, with an additional modification of a deletion of 1 adenosine in the 10-A polynucleotide sequence in exon 10 (codons 771-774) of the ATR cDNA sequence (Applied Biological Materials).

Techniques: Mutagenesis, Sequencing, Functional Assay

(A) representative images of log growth phase HCT-116 ATR-WT and D15 (heterozygous ATR-I774Yfs*5) labeled with EdU to show proliferation in the absence of thymidine treatment as indicated by red staining (DAPI staining to indicate DNA). (B) EdU incorporation into HCT-116 ATR-WT and a representative ATR heterozygotic mutant HCT-116 cell clone (D15) are shown in cells treated with 2mM thymidine for 24 hours prior to EdU treatment. (C) Quantification of EdU incorporation into nuclei of HCT-116 ATR-WT and all three ATR heterozygotic mutant HCT-116 cell clones ± 2 μM thymidine. (D) Quantification of EdU incorporation into observed micronuclei in HCT-116 ATR-WT and all three ATR heterozygotic mutant HCT-116 cell clones ± 2 μM thymidine. (E) Quantification of micronuclear incidence in HCT-116 ATR-WT and all three ATR heterozygotic mutant HCT-116 cell clones ± 2 μM thymidine. For (C), (D) , and (E) , * denotes p <0.05 using Fisher’s Exact test). (F) A chart depicting the cell counts for each clone in the two treatment conditions, along with EdU positive cell counts, total number of observed micronuclei, and the number of EdU positive micronuclei. These values were used to determine statistical significances as shown in (C), (D), and (E).

Journal: bioRxiv

Article Title: ATR-I774Yfs*5 promotes genomic instability through micronuclei formation

doi: 10.1101/2022.03.10.483800

Figure Lengend Snippet: (A) representative images of log growth phase HCT-116 ATR-WT and D15 (heterozygous ATR-I774Yfs*5) labeled with EdU to show proliferation in the absence of thymidine treatment as indicated by red staining (DAPI staining to indicate DNA). (B) EdU incorporation into HCT-116 ATR-WT and a representative ATR heterozygotic mutant HCT-116 cell clone (D15) are shown in cells treated with 2mM thymidine for 24 hours prior to EdU treatment. (C) Quantification of EdU incorporation into nuclei of HCT-116 ATR-WT and all three ATR heterozygotic mutant HCT-116 cell clones ± 2 μM thymidine. (D) Quantification of EdU incorporation into observed micronuclei in HCT-116 ATR-WT and all three ATR heterozygotic mutant HCT-116 cell clones ± 2 μM thymidine. (E) Quantification of micronuclear incidence in HCT-116 ATR-WT and all three ATR heterozygotic mutant HCT-116 cell clones ± 2 μM thymidine. For (C), (D) , and (E) , * denotes p <0.05 using Fisher’s Exact test). (F) A chart depicting the cell counts for each clone in the two treatment conditions, along with EdU positive cell counts, total number of observed micronuclei, and the number of EdU positive micronuclei. These values were used to determine statistical significances as shown in (C), (D), and (E).

Article Snippet: ATR-I774Yfs*5-GFP is a modification of the ATR-WT-GFP PCDNA 3.1 plasmid, with an additional modification of a deletion of 1 adenosine in the 10-A polynucleotide sequence in exon 10 (codons 771-774) of the ATR cDNA sequence (Applied Biological Materials).

Techniques: Labeling, Staining, Mutagenesis, Clone Assay